THE U.S. FDA GRANTS ORPHAN DRUG DESIGNATION FOR LUNDBECK'S INVESTIGATIONAL ANTI-ACTH MONOCLONAL ANTIBODY ASEDEBART FOR TREATMENT OF ENDOGENOUS CUSHING'S SYNDROME

Reuters · 2d ago

Please log in to view news